# Bifidobacterium breve A1

**Canonical URL:** https://ingredients.hermeticasuperfoods.com/ingredients/bifidobacterium-breve-a1
**Data Source:** Hermetica Superfoods Ingredient Encyclopedia
**Updated:** 2026-03-25
**Evidence Score:** 2 / 10
**Category:** Fermented/Probiotic
**Also Known As:** Bifidobacterium breve strain A1, B. breve A1, Bifidobacterium breve A-1, B. breve strain A1, Bifido A1, Bifidobacterium breve A1 probiotic

## Overview

Bifidobacterium breve A1 is a specific [probiotic](/ingredients/condition/gut-health) strain that acts on the gut-brain axis, primarily by modulating hippocampal gene expression and upregulating brain-derived neurotrophic factor ([BDNF](/ingredients/condition/cognitive)). Its most studied application is neuroprotection in Alzheimer's disease models, where it reduces neuro[inflammation](/ingredients/condition/inflammation) by suppressing amyloid-beta-induced immune overactivation.

## Health Benefits

• May improve [cognitive function](/ingredients/condition/cognitive) and memory in Alzheimer's disease models (preliminary animal evidence only)
• Supports brain health by normalizing hippocampal gene expression and upregulating BDNF (preliminary animal evidence)
• Reduces neuro[inflammation](/ingredients/condition/inflammation) and excessive immune responses in the brain (preliminary animal evidence)
• Increases beneficial short-chain fatty acid (acetate) production in the gut (preliminary animal evidence)
• Shows [probiotic](/ingredients/condition/gut-health) properties including acid and bile salt tolerance for gut colonization (in-vitro evidence)

## Mechanism of Action

Bifidobacterium breve A1 modulates the gut-brain axis by altering microbial metabolite production, which suppresses amyloid-beta-triggered activation of NF-κB signaling pathways responsible for neuroinflammatory cytokine release including TNF-α and IL-6. The strain upregulates hippocampal [BDNF](/ingredients/condition/cognitive) expression, a neurotrophin critical for synaptic plasticity and neuronal survival, by normalizing dysregulated gene expression patterns observed in Alzheimer's disease models. Additionally, it is hypothesized to reduce excessive microglial activation by modulating short-chain fatty acid (SCFA) production in the gut, which communicates [anti-inflammatory](/ingredients/condition/inflammation) signals to the central nervous system via the vagus nerve.

## Clinical Summary

The evidence base for Bifidobacterium breve A1 is currently limited almost entirely to preclinical animal studies, primarily in amyloid-beta-infused mouse models of Alzheimer's disease. These rodent studies demonstrated measurable improvements in spatial [memory](/ingredients/condition/cognitive) tasks and normalization of hippocampal gene expression profiles, alongside quantifiable reductions in pro-[inflammatory](/ingredients/condition/inflammation) markers. No large-scale randomized controlled trials in human populations have been published as of the current literature review, making it premature to draw definitive clinical conclusions. The strain shows mechanistically plausible benefits for neuroinflammatory conditions, but human dosing, efficacy, and long-term safety have not been established.

## Nutritional Profile

Bifidobacterium breve A1 is a live probiotic bacterial strain and does not contribute meaningful macronutrients (calories, fats, carbohydrates, or protein) in the quantities typically consumed (1–100 billion CFU per serving). As a bacterial organism, its nutritional contributions are functional rather than macronutritional. Bioactive compounds of note include: cell wall components such as peptidoglycan and lipoteichoic acid, which interact with host immune receptors (TLR2, NOD receptors); exopolysaccharides (EPS) that modulate gut mucosal [immunity](/ingredients/condition/immune-support) and may influence [microbiome](/ingredients/condition/gut-health) composition; and metabolic byproducts including short-chain fatty acids, most notably acetate, produced through fermentation of dietary fibers — acetate levels measurably increase in cecal and fecal samples in animal models supplemented with B. breve A1. The strain also produces folate (vitamin B9) as a metabolic byproduct, consistent with other Bifidobacterium species, though strain-specific quantification for A1 is not well-characterized in published literature. B. breve A1 upregulates brain-derived neurotrophic factor ([BDNF](/ingredients/condition/cognitive)) expression in hippocampal tissue (demonstrated in murine models), acting via the gut-brain axis rather than direct nutrient delivery. Bioavailability note: as a probiotic, efficacy depends on survival through gastric acid and bile — B. breve demonstrates moderate acid tolerance relative to other Bifidobacterium species; encapsulated or enteric-coated delivery formats improve viable cell delivery to the colon. No significant vitamin, mineral, or fiber content is delivered to the host at standard supplemental doses.

## Dosage & Preparation

No clinically studied human dosages are available for B. breve A1. Preclinical mouse studies used lyophilized powder administered orally, but exact CFU dosages were not specified. Consult a healthcare provider before starting any new supplement.

## Safety & Drug Interactions

Bifidobacterium breve A1 is generally considered safe for healthy adults, as Bifidobacterium species have a long history of use in food and probiotic products with a well-established safety profile. Individuals who are immunocompromised, have compromised [gut barrier](/ingredients/condition/gut-health)s, or are critically ill should consult a physician before use, as probiotic supplementation carries a small risk of bacteremia in these populations. No specific drug interactions have been formally documented for this strain, but concurrent use with broad-spectrum antibiotics will likely reduce its viability and efficacy. Safety data during pregnancy and lactation specific to the A1 strain is insufficient, and pregnant individuals should seek medical guidance before supplementing.

## Scientific Research

Current evidence for B. breve A1 is limited to preclinical animal models with no human clinical trials, RCTs, or meta-analyses identified. Mouse studies using Alzheimer's disease models showed improvements in spatial recognition (Y-maze tests) and learning/[memory](/ingredients/condition/cognitive) (passive avoidance tests), with effects comparable to cholinesterase inhibitors.

## Historical & Cultural Context

No historical or traditional medicinal use is documented for B. breve A1, as it is a modern isolated strain without roots in traditional medicine systems. It was developed as part of contemporary [probiotic](/ingredients/condition/gut-health) research focusing on gut-brain axis connections.

## Synergistic Combinations

Other Bifidobacterium strains, Lactobacillus species, [Prebiotic](/ingredients/condition/gut-health) fibers, Omega-3 fatty acids, [BDNF](/ingredients/condition/cognitive)-supporting nutrients

## Frequently Asked Questions

### What makes Bifidobacterium breve A1 different from other Bifidobacterium strains?

Bifidobacterium breve A1 is a specific strain distinguished by its documented effects on hippocampal gene expression and BDNF upregulation, which have not been demonstrated for generic Bifidobacterium breve strains. Strain-level specificity matters in probiotics because health effects are not interchangeable across strains even within the same species. The A1 designation refers to a proprietary isolate studied specifically for its gut-brain axis activity in neurological disease models.

### Can Bifidobacterium breve A1 help with Alzheimer's disease?

Current evidence is limited to amyloid-beta-infused mouse models, where oral administration of Bifidobacterium breve A1 improved spatial memory performance and reduced hippocampal neuroinflammatory markers including suppressed NF-κB-driven cytokines. No human clinical trials have confirmed these effects in Alzheimer's patients, so it cannot be recommended as a treatment for Alzheimer's disease. It remains a promising area of research requiring well-designed randomized controlled trials before any clinical claims can be supported.

### What is the typical dosage of Bifidobacterium breve A1?

No established human clinical dosage has been validated for Bifidobacterium breve A1, as human trials are lacking. Animal studies have used doses scaled to body weight that roughly translate to several billion CFU (colony-forming units) daily in human equivalents, which is consistent with standard probiotic supplement doses of 1–10 billion CFU. Until human pharmacokinetic and dose-response studies are conducted, any dosage recommendation remains speculative.

### How does Bifidobacterium breve A1 affect BDNF levels?

In Alzheimer's disease mouse models, oral supplementation with Bifidobacterium breve A1 was associated with normalization of hippocampal gene expression, including upregulation of BDNF — a neurotrophin that supports synaptic plasticity, neuronal survival, and memory consolidation. The proposed mechanism involves gut microbiome-driven SCFA production and vagal signaling that counteracts amyloid-beta-induced suppression of BDNF transcription. This effect has not yet been replicated or measured in human subjects.

### Is Bifidobacterium breve A1 safe to take daily?

For healthy adults, Bifidobacterium breve A1 is expected to be safe for daily use based on the established safety record of Bifidobacterium species used in fermented foods and dietary supplements globally. Common mild side effects of probiotics in general include transient bloating or gas during the initial days of supplementation. Immunocompromised individuals, those with central venous catheters, or patients with severe intestinal disease should avoid probiotic use without physician supervision due to a small risk of systemic infection.

### Does Bifidobacterium breve A1 produce enough short-chain fatty acids to significantly impact health?

Bifidobacterium breve A1 produces acetate, a short-chain fatty acid (SCFA) that crosses the blood-brain barrier and may support neuroinflammation reduction. However, the quantity produced depends on individual gut microbiota composition, diet, and the number of viable cells consumed, making clinical significance variable between individuals. Current evidence is primarily from animal models, and human studies measuring SCFA levels from this specific strain are limited.

### Is Bifidobacterium breve A1 effective for people without Alzheimer's disease or cognitive decline?

Most research on Bifidobacterium breve A1 focuses on Alzheimer's disease models, with limited evidence for general cognitive enhancement in healthy individuals. The strain may support baseline brain health through BDNF upregulation and neuroinflammation reduction, but healthy people typically benefit less from targeted cognitive probiotics than those with existing neurodegenerative conditions. Additional human studies are needed to determine preventive benefits in cognitively normal populations.

### How long does it take for Bifidobacterium breve A1 to colonize the gut and produce measurable effects?

Probiotics typically require 2-4 weeks of consistent use to establish meaningful gut colonization, though initial microbial changes may occur within days. For cognitive or neuroinflammation benefits specific to Bifidobacterium breve A1, animal studies suggest effects develop over weeks to months, but human timelines remain poorly characterized. Discontinuation usually results in decline within 1-2 weeks, indicating colonization requires ongoing supplementation.

---

*Source: Hermetica Superfoods Ingredient Encyclopedia — https://ingredients.hermeticasuperfoods.com*
*License: CC BY-NC-SA 4.0 — Attribution required. Commercial use: admin@hermeticasuperfoods.com*